Literature DB >> 11084394

[ACTH resistance syndromes].

D Naville1, A Penhoat, M Bégeot.   

Abstract

ACTH resistance syndromes consist of a group of rare disorders with three various molecular etiologies. However, all these diseases share the feature of severe glucocorticoid adrenal insufficiency. The simplest disorder is the isolated familial glucocorticoid deficiency (FGD) which could be divided in two different types. In FGD type 1, ACTH receptor mutations have been described and are responsible for the loss of function of the receptor, leading to the ACTH unresponsiveness. Patients with FGD type 2 show the same phenotype as in the previous syndrome but no mutation of the ACTH receptor has been reported in these cases. It has been proposed that morbidity of one or several other gene(s) could be responsible for this syndrome although there is no information about their chromosomal localization. The third molecular form of the disease corresponds to the Triple A syndrome for the triad of association "ACTH resistance, Achalasia, Alacrima", thus reflecting a large spectrum of additional symptoms. It has recently been reported that the morbid gene in this last syndrome maps to chromosome 12q13. The aim of this review is to examine the clinical aspect as well as the current knowledge of the molecular and genetic aspects of the different forms of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11084394

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  2 in total

Review 1.  ACTH Receptor (MC2R) Specificity: What Do We Know About Underlying Molecular Mechanisms?

Authors:  Davids Fridmanis; Ance Roga; Janis Klovins
Journal:  Front Endocrinol (Lausanne)       Date:  2017-02-06       Impact factor: 5.555

2.  The Genetic Perspective of Familial Glucocorticoid Deficiency: In Silico Analysis of Two Novel Variants.

Authors:  Katayoun Heshmatzad; Nejat Mahdieh; Ali Rabbani; Abdolah Didban; Bahareh Rabbani
Journal:  Int J Endocrinol       Date:  2020-09-01       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.